AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021
Dec 20, 2021
29977_dirs_2021-12-20_daff367b-d06f-4784-b697-55ae95f3e544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-16
Reporting Person: VAGELOS P ROY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-16 | Common Stock | I | 19 | $634.7 | Disposed | 2202 | Indirect |
| 2021-12-16 | Common Stock | I | 107 | $635.03 | Disposed | 2095 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 318669 | Direct |
| Common Stock | 141630 | Indirect |
| Common Stock | 37747 | Indirect |
| Common Stock | 3609 | Indirect |
Footnotes
F1: Represents volume-weighted average price of sales of 107 shares of Company stock on December 16, 2021 at prices ranging from $635.00 to $635.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 16, 2021 at each separate price.
F2: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.